ESMO 2026: Amgen's Imdelltra and AstraZeneca's Imfinzi Reduce Mortality Risk by Almost 60% in Patients with Small Cell Lung Cancer

ESMO 2026: Amgen’s Imdelltra and AstraZeneca’s Imfinzi Reduce Mortality Risk by Almost 60% in Patients with Small Cell Lung Cancer